Radio-labelled antibody fragments for use in the prevention and/or treatment of cancer
The application provides polypeptides comprising or essentially consisting of at least one heavy chain variable domain of a heavy chain antibody (V HH ) or functional fragments thereof, wherein said V HH or functional fragment thereof specifically binds to a target protein that is present on and/or specific for a solid tumor or cancer cell, e.g., HER2. The application further provides nucleic acids encoding such polypeptides; methods for preparing such polypeptides; host cells expressing or capable of expressing such polypeptides; compositions, and in particular to pharmaceutical compositions that comprise such polypeptides, nucleic acids and/or host cells. The application further provides such polypeptides, nucleic acids, host cells and/or compositions, for use in methods for the prevention and/or treatment of cancer.
1. A method for the treatment of cancer, the method comprising:
administering to a subject in need thereof an effective amount of a radiolabelled, untagged monovalent heavy chain variable domain derived from a heavy chain antibody (V HH ), or a functional fragment thereof, which specifically binds to HER2 that is present on a cancer cell or solid tumor, wherein the radiolabelled, untagged monovalent VHH comprises one of the CDR combinations selected from the group consisting of: a CDR1 region having SEQ ID NO:1,a CDR2 region having SEQ ID NO:2, and a CDR3 region having SEQ ID NO:3,and a CDR1 region having SEQ ID NO:4, a CDR2 region having SEQ ID NO:5, and a CDR3 region having SEQ ID NO:6.
2. The method of claim 1 , wherein the radiolabelled, untagged monovalent V HH or functional fragment thereof is labeled with a halogen radio-isotope.
3. The method of claim 2 , wherein the radiolabelled, untagged monovalent V HH or functional fragment thereof is labeled with 131-Iodine.
4. The method of claim 1 , wherein the radiolabelled, untagged monovalent V HH or functional fragment thereof is labeled with 131-Iodine using N-succinimidyl-4-guanidinomethyl-3-[I-131]iodobenzbate ([I-131]SGMIB) or a suitable derivative or variant thereof.
5. The method of claim 1 , wherein the radiolabelled, untagged monovalent V HH or functional fragment thereof is labeled with a radio-isotope chosen from the group consisting of α-emitting radioisotopes and β-emitting radioisotopes.
6. The method of claim 5 , wherein the radiolabelled, untagged monovalent V HH or functional fragment thereof is labeled with a radio-isotope chosen from the group consisting of Actinium-225, Astatine-211, Bismuth-212, Bismuth-213, Caesium-137, Chromium-51, Cobalt-60, Dysprosium -165, Erbium-169, Fermium-255, Gold-198, Holium-166, Iodine-125, Iodine-131, Iridium-192, Iron-59, Lead-212, Lutetium-177, Molydenum-99, Palladium-103, Phosphorus-32, Potassium-42, Rhenium-186, Rhenium-188, Samarium-153, Technitium-99m, Radium-223, Ruthenium-106, Sodium-24, Strontium-89, Terbium-149, Thorium-227, Xenon-133, Ytterbium-169, Ytterbium-177and Yttrium-90.
7. The method of claim 1 , wherein the radiolabelled, untagged monovalent V HH or functional fragment thereof is administered to the subject in a calculated mean effective dose of between 0.002 and 0.1 mSv/MBq in said subject.
8. The method of claim 1 , wherein the radiolabelled, untagged monovalent V HH or functional fragment thereof is administered to the subject at an administration interval of between once a day and once a month or between once a month and once a year.
9. The method of claim 1 , wherein the radiolabelled, untagged monovalent V HH , or functional fragment thereof, has at least 80% amino acid identity with at least one of the amino acid sequences of SEQ ID NOs:7 and 8.
10. The method of claim 9 , wherein the radiolabelled, untagged monovalent V HH , or functional fragment thereof, is identical with at least one of the amino acid sequences of SEQ ID NOs:7 and 8.
11. The method of claim 1 , wherein the cancer is breast cancer.
12. The method of claim 1 , wherein the method further comprises performing immunotherapy on the subject.
13. The method of claim 1 , wherein the radiolabelled, monovalent V HH or functional fragment thereof is administered to the subject intravenously , intrathecally, or intraperitoneally.
14. The method of claim 1 , wherein the radiolabelled, monovalent V HH or functional fragment thereof is non-lifetime extended.
15. The method of claim 1 , wherein residual malignant cells are targeted in the subject.
16. The method of claim 15 , wherein minimal residual disease is reduced or eliminated in the subject.
17. The method of claim 15 , wherein the residual malignant cells are present in the patient after remission.
18. The method of claim 1 , wherein the radiolabelled, untagged monovalent VHH comprises: a CDR1 region having SEQ ID NO:1, a CDR2 region having SEQ ID NO:2, and a CDR3 region having SEQ ID NO:3.
19. The method of claim 1 , wherein the radiolabelled, untagged monovalent VHH comprises: a CDR1 region having SEQ ID NO:4, a CDR2 region having SEQ ID NO:5, and a CDR3 region having SEQ ID NO:6.